CAR-T Cell Therapy

CAR-T Cell Detection and Quantification with Dextramer® Technology

Dextramer[®] reagents may provide a sensitive solution for direct detection and quantification of CAR-positive cells by flow cytometry.

Using Dextramer[®] technology, our Custom Solutions and Services team can work with you to develop custom antigen multimers and optimize detection of your CAR-T cells.



PRECISION IMMUNE MONITORING

How does it work?



Applications of Dextramer® Technology in CAR-T Cell Therapy



- Direct CAR-T cell detection
- Enhanced sensitivity for low-affinity CAR-Ts, due to the high avidity of Dextramer[®] technology and multiple fluorophores
- Assessment of transduction levels
- Determine the % of CAR-T-positive cells
- Demonstrate that the infusion product meets defined lot release criteria
- Monitor kinetics and persistence of infused CAR-T cells in patient blood samples
- Deeper characterization of target-specific CAR-T cells with gene and surface marker expression by single-cell multi-omics

IMMUDEX www.immudex.com ORDERING ordering@immudex.com CUSTOMER SUPPORT customer@immudex.com



Ø

RFAD THE **FDA GUIDANCE**

Discover New CAR-T Antibodies

Use dCODE Klickmer® for rapid antibody discovery by single-cell multi-omics of antigenspecific B cells. Load target antigens onto dCODE Klickmer® to identify and sequence antibodyproducing B cells.

Learn more: immudex.com/antibody-discovery

Use pMHC Monomers for animal immunization and biotinylated pMHC Monomers for screening TCR-like antibody libraries via phage display.

Learn more: immudex.com/monomers



FDA Guidance for CAR-T Cell Products

The most recent guidance from the FDA regarding the development of CAR-T cell products includes recommendations for detecting and evaluating the CAR product. Our products can assist you in adhering to this guidance.

Manufacturing and Lot Release

"Control of the manufacturing process and appropriate in process and lot release testing are crucial to ensure CAR-T cell safety, quality and lot-to-lot consistency."

Direct Detection of CAR-T cells

"Direct detection of the CAR to determine the percentage of CAR-positive cells.

Antigen Recognition of CAR Construct

Assess the ability of each antigen recognition domain to specifically bind to its target.

CAR-T levels in Starting Material

If pre-treated with another CAR-therapy, evaluation of the previously administered CAR T cell levels in the cellular starting material may be appropriate.

Transduced T cells and Biological Activity

FDA recommends to examine "uncontrolled proliferation, in vitro and in vivo testing for T cell clonality, karyotypic analysis, TCR repertoire analysis, and specificity for viral antigens through ex vivo stimulation and recognition assays" to document the biological activity of transduced T cells.

Dextramer® Technology

Dextramer[®] technology enables direct CAR detection for development of assays to assess the % of CAR-positive cells for lot release testing or for evaluation of starting material by flow cytometry.

dCODE[®] Technology

With dCODE® technology, Immudex offers a wide range of viral specificities to characterize the clonality and repertoire of antigen-specific TCRs through V(D)J sequencing.

Interested in learning more? Please contact us at customer@immudex.com

©Immudex ApS Denmark, 2024

For research use only. Not for use in diagnostic or therapeutic procedures. BV421 is equivalent to Brilliant Violet™ 421, which is a trademark or registered trademark of Becton, Dickinson and Company or its affiliates, and is used under license. Powered by BD Innovation.